Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Cost of Revenue (2020 - 2025)

Gyre Therapeutics (GYRE) has disclosed Cost of Revenue for 6 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue fell 88.12% to $1.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $69.7 million, a 56.14% increase, with the full-year FY2024 number at $57.5 million, down 5.96% from a year prior.
  • Cost of Revenue was $1.6 million for Q3 2025 at Gyre Therapeutics, down from $15.2 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $53.4 million in Q4 2022 to a low of $770000.0 in Q2 2024.
  • A 5-year average of $12.2 million and a median of $2.5 million in 2021 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: skyrocketed 2077.67% in 2022, then crashed 95.72% in 2024.
  • Gyre Therapeutics' Cost of Revenue stood at $2.5 million in 2021, then surged by 2077.67% to $53.4 million in 2022, then plummeted by 45.34% to $29.2 million in 2023, then soared by 44.01% to $42.1 million in 2024, then plummeted by 96.13% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Cost of Revenue are $1.6 million (Q3 2025), $15.2 million (Q2 2025), and $10.8 million (Q1 2025).